Literature DB >> 33277346

Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study.

Jiandong Zhou1, Xiansong Wang2, Sharen Lee3, William Ka Kei Wu2, Bernard Man Yung Cheung4, Qingpeng Zhang5, Gary Tse6.   

Abstract

Entities:  

Keywords:  COVID-19; proton pump inhibition

Year:  2020        PMID： 33277346     DOI： 10.1136/gutjnl-2020-323668

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  14 in total

1.  Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.

Authors:  Thomas Marjot; Christiane S Eberhardt; Tobias Boettler; Luca S Belli; Marina Berenguer; Maria Buti; Rajiv Jalan; Mario U Mondelli; Richard Moreau; Daniel Shouval; Thomas Berg; Markus Cornberg
Journal:  J Hepatol       Date:  2022-07-20       Impact factor: 30.083

Review 2.  Gastroduodenal injury and repair: novel targets for therapeutic intervention.

Authors:  Susan J Hagen
Journal:  Curr Opin Gastroenterol       Date:  2022-11-01       Impact factor: 2.741

3.  Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis.

Authors:  Simone Bastrup Israelsen; Martin Thomsen Ernst; Andreas Lundh; Lene Fogt Lundbo; Håkon Sandholdt; Jesper Hallas; Thomas Benfield
Journal:  Clin Gastroenterol Hepatol       Date:  2021-05-11       Impact factor: 13.576

4.  An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19.

Authors:  Jan Homolak; Ivan Kodvanj; Vladimir Trkulja
Journal:  Clin Drug Investig       Date:  2021-02-19       Impact factor: 2.859

5.  Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.

Authors:  Chia Siang Kow; Ismail Abdul Sattar Burud; Syed Shahzad Hasan
Journal:  Mayo Clin Proc       Date:  2021-03-05       Impact factor: 7.616

6.  Interaction effects between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and steroid or antiviral therapies in COVID-19: A population-based study.

Authors:  Jiandong Zhou; Gary Tse; Sharen Lee; Tong Liu; Zhidong Cao; Daniel Dajun Zeng; Keith Sai Kit Leung; Abraham Ka Chung Wai; Ian Chi Kei Wong; Bernard Man Yung Cheung; Qingpeng Zhang
Journal:  J Med Virol       Date:  2021-03-09       Impact factor: 20.693

7.  Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.

Authors:  Jiandong Zhou; Sharen Lee; Xiansong Wang; Yi Li; William Ka Kei Wu; Tong Liu; Zhidong Cao; Daniel Dajun Zeng; Keith Sai Kit Leung; Abraham Ka Chung Wai; Ian Chi Kei Wong; Bernard Man Yung Cheung; Qingpeng Zhang; Gary Tse
Journal:  NPJ Digit Med       Date:  2021-04-08

8.  Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.

Authors:  Jiandong Zhou; Sharen Lee; Keith Sai Kit Leung; Abraham Ka Chung Wai; Tong Liu; Ying Liu; Dong Chang; Wing Tak Wong; Ian Chi Kei Wong; Bernard Man Yung Cheung; Qingpeng Zhang; Gary Tse
Journal:  ESC Heart Fail       Date:  2022-02-07

9.  Development of a predictive risk model for all-cause mortality in patients with diabetes in Hong Kong.

Authors:  Sharen Lee; Jiandong Zhou; Keith Sai Kit Leung; William Ka Kei Wu; Wing Tak Wong; Tong Liu; Ian Chi Kei Wong; Kamalan Jeevaratnam; Qingpeng Zhang; Gary Tse
Journal:  BMJ Open Diabetes Res Care       Date:  2021-06

10.  Common drugs, vitamins, nutritional supplements and COVID-19 mortality.

Authors:  Steven Lehrer; Peter H Rheinstein
Journal:  Int J Funct Nutr       Date:  2021-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.